CN106334060A - 一种治疗肥胖型多囊卵巢综合征的药物组合物 - Google Patents
一种治疗肥胖型多囊卵巢综合征的药物组合物 Download PDFInfo
- Publication number
- CN106334060A CN106334060A CN201610955074.XA CN201610955074A CN106334060A CN 106334060 A CN106334060 A CN 106334060A CN 201610955074 A CN201610955074 A CN 201610955074A CN 106334060 A CN106334060 A CN 106334060A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- rhizoma
- radix
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 206010036049 Polycystic ovaries Diseases 0.000 title abstract description 15
- 238000011282 treatment Methods 0.000 claims description 28
- 208000008589 Obesity Diseases 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000005461 lubrication Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 74
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 30
- 208000026435 phlegm Diseases 0.000 abstract description 30
- 210000003734 kidney Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 21
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 230000004087 circulation Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 238000010792 warming Methods 0.000 abstract description 6
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract 2
- 238000003379 elimination reaction Methods 0.000 abstract 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000016087 ovulation Effects 0.000 description 11
- 241000721047 Danaus plexippus Species 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000027758 ovulation cycle Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 239000003098 androgen Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000002787 reinforcement Effects 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 201000005670 Anovulation Diseases 0.000 description 3
- 206010002659 Anovulatory cycle Diseases 0.000 description 3
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 231100000552 anovulation Toxicity 0.000 description 3
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 3
- 229960003608 clomifene Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000825107 Hierochloe Species 0.000 description 2
- 235000015466 Hierochloe odorata Nutrition 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003457 anti-vomiting effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000009530 yishen Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗肥胖型多囊卵巢综合征的药物组合物,其原料组成为:姜半夏4‑8份,仙灵脾25‑35份,苍术8‑12份,茯苓16‑24份,陈皮10‑14份,续断25‑35份,香附8‑12份,丹参16‑24份,牛膝8‑12份,车前子8‑12份,肉桂4‑8份,炙甘草4‑8份。本发明的药物组合物所选药材配伍相宜,组方精炼,在功能上相辅相成,以利湿除痰为目的,集祛痰、温肾、行气、健脾、活血、通利为一体,疗效显著;在药性上相制相佐,毒副反应少。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种治疗肥胖型多囊卵巢综合征的药物组合物。
背景技术
多囊卵巢综合征(polycystic ovary syndrome,PCOS)是以长期无排卵和雄激素过多为特征的常见妇科内分泌代谢性疾病,是一种发病多因性、临床表现多样化的综合征。在育龄期妇女中患病率高达5~12%,其主要临床表现为月经失调、不孕、肥胖、多毛、痤疮等,不仅增加妊娠期糖尿病和妊娠高血压的危险性,而且增加子宫内膜癌、糖尿病、动脉粥样硬化症、冠心病等远期代谢疾病出现的风险,严重影响妇女的生活质量。长时间的无排卵给妇女的身心健康带来的危害,不利于家庭的和谐和社会的稳定。目前本病发病率有上升趋势,约50%的患者超重或肥胖,而且许多研究表明肥胖型患者的代谢紊乱发病率及病情严重程度明显高于非肥胖型。
对于多囊卵巢综合征的治疗,目前西医通常釆用克罗米芬等促排卵药物治疗、釆用二甲双胍等改善胰岛素抵抗以减轻肥胖等症状,从而提高妊娠率。但是以上药物治疗效果不佳且有一定的副作用,而多囊卵巢综合征患者通常需要较为长期的服药治疗过程,因此寻求安全有效的多囊卵巢综合征的治疗药物显得尤为迫切。
发明内容
针对上述现有技术,本发明的目的是提供一种疗效显著、成本低廉、毒副作用小的治疗肥胖型多囊卵巢综合征的药物组合物。现代中医学者多数认为本病与肾、肝、脾三脏关系密切,肾虚乃患者致病之本,痰湿为致病之标,而肥胖型患者多属痰湿体质,结合现代医学认
为降低体重为患者的一线处理原则,故临床治疗肥胖型患者首重祛痰湿,改善痰湿体质,待痰湿体质改善,气血运行调畅、胞脉通畅,而后方可再图缓治,以补肾调周为主,恢复正常排卵。本发明拟成补肾燥湿化痰方,临床运用改善月经及内分泌、代谢效果颇佳。
为实现上述目的,本发明采用下述技术方案:
本发明第一方面,提供一种治疗肥胖型多囊卵巢综合征的药物组合物,其原料组成为:
姜半夏4-8份,仙灵脾25-35份,苍术8-12份,茯苓16-24份,陈皮10-14份,续断25-35份,香附8-12份,丹参16-24份,牛膝8-12份,车前子8-12份,肉桂4-8份,炙甘草4-8份。
本发明所述治疗肥胖型多囊卵巢综合征的药物组合物,优选的组方为:
姜半夏6份,仙灵脾30份,苍术10份,茯苓20份,陈皮12份,续断30份,香附10份,丹参20份,牛膝10份,车前子10份,肉桂6份,炙甘草6份。
本发明药物组合物的配伍机理:以姜半夏、仙灵脾为君药,以陈皮、苍术、茯苓、香附、续断共为臣药,陈皮、苍术、茯苓、香附四药相辅与姜半夏相须为用,增强其燥湿化痰、理气行滞之力,续断补肝肾,调血脉,与仙灵脾相须为用,共奏补肾温阳之功。
痰湿是由于脏腑功能失调所产生的病理产物,脏腑功能失调首先与肾虚有关,亦与脾胃虚弱,痰湿内生有关。故痰湿病症,多属本虚标实,治疗需标本兼治。化痰需要理气,利湿需要气机通畅,故采用化痰燥湿,理气通利之法以治其标,而治本的重点在于补肾,特别是温补肾阳。故发明的药物组合物以姜半夏、仙灵脾为君药。半夏辛温性燥,善能燥湿化痰,且又和胃降逆,煎加生姜炮制,既能制半夏之毒,又能协助半夏化痰降逆、和胃止呕;仙灵脾补肾阳,祛风湿,合姜半夏共为君药,标本兼治。臣以陈皮、苍术、茯苓、香附,既可理气行滞,又能燥湿化痰。茯苓另可健脾渗湿,以杜生痰之源。续断补肝肾,调血脉,合仙灵脾共奏补肾温阳之功。痰湿内阻,气机不利,瘀血内生,痰瘀互结,以致月经后期、量少、闭经。故佐以丹参活血祛瘀通经,肉桂温通血脉,合君药相使配伍;车前子利水通利,与姜半夏相须配伍;牛膝补肝肾,合仙灵脾、续断相须配伍,又合丹参逐瘀通经。甘草为使,调和诸药。全方共奏补肾化痰,活血通经之效。
本发明通过将多味中药进行配伍,药物之间共同发挥了化痰燥湿、理气通利、温补肾阳的作用,具有明显的增效作用,充分发挥了相须相使的配伍关系。
方中君药姜半夏,与臣药茯苓、陈皮、甘草合用,具有降血脂、降血糖、改善胰岛素抵抗的作用。故姜半夏、茯苓、陈皮、甘草四药的配伍是治疗痰湿型多囊卵巢综合征的必备组成。臣药香附,《本草纲目》言其“乃气病之总司,女科之主帅也”。是妇科理气调经的必备配伍药物。药理研究亦证实香附的雌激素样作用是其治疗月经不调的主要依据。臣药苍术燥湿健脾,本方针对痰湿标本兼治,药理实验证实苍术具有降血糖的功能,与君药姜半夏,臣药茯苓、陈皮、甘草配伍使用,可改善PCOS的代谢障碍。因此,上述药物组合物的配伍是天南星、白芥子、川贝等祛痰药物及枳壳、青皮、佛手、香橼等理气药所不能替代的。
君药仙灵脾、续断为传统的补肾壮阳类中药,现代药理研究发现仙灵脾能增强下丘脑-垂体-性腺轴及肾上腺皮质轴、胸腺轴等内分泌系统的分泌功能。续断含维生素E,具有调节内分泌的功能。本方与化痰行气药物配伍,治疗痰湿标本兼治。不能以巴戟天、补骨脂、仙茅等补肾药所取代。
综上所述,本方所选药材配伍相宜,组方精炼,在功能上相辅相成,以利湿除痰为目的,集祛痰、温肾、行气、健脾、活血、通利为一体,疗效显著;在药性上相制相佐,毒副反应少,服用安全。
本发明的治疗肥胖型多囊卵巢综合征的药物组合物中,各原料组分是一个有机的整体,缺一不可。发明人在研发过程中发现,减少上述组合物中的任何一种原料组分,或以具有相似药性的原料药对本发明药物组合物的原料组分进行替换,则药物组合物整体的作用效果显著降低;在本发明的药物组合物的基础上再增加其他的原料组分,药物组合物的整体效果并未有明显的改善,甚至有药物组合物的整体效果降低的情况出现。
上述治疗肥胖型多囊卵巢综合征的药物组合物可直接将各原料粉碎,混合均匀后使用;或加水煎煮;也可以按照其他方法制备。在本发明的一个具体实施方式中,上述治疗肥胖型多囊卵巢综合征的制备方法为:
将姜半夏、仙灵脾、苍术、茯苓、陈皮、续断、香附、丹参、牛膝、车前子、肉桂和炙甘草混合,加水煎煮两次,滤过(第一次加7-10倍量水,煎煮30分钟;第二次加5-8倍量水,煎煮20分钟),合并滤液,即得。
中药成分复杂,一种药材中既有水溶性成分,又有油溶性或醇溶性成分,且有些活性成分在高温下容易失活,因此通过选择合适的提取方法和提取工艺对中药有效成分进行提取分离,可以最大限度的提取出有效成分并保证有效成分的活性,从而保证产品的临床效果。
经试验验证,采用上述制备方法,可以最大限度的提取出中药组合物中的有效成分并保证有效成分的活性,从而保证产品的临床效果。
上述药物组合物在制备治疗肥胖型多囊卵巢综合征的药物制剂中的应用也是本发明保护的范围。
本发明第二方面,提供一种治疗肥胖型多囊卵巢综合征的药物制剂,由上述药物组合物和药学上可接受的辅料制备而成。
上述药物制剂可以制成各种药物剂型,如丸剂、胶囊剂、片剂、散剂、颗粒剂或口服液等。
所述药学上可接受的辅料为药物制剂中的常规辅料,如:崩解剂、润滑剂、黏合剂等;优选为甘油、丁二醇、海藻糖、甜菜碱、淀粉、羧甲基纤维素钠中的一种或多种。
本发明的药物组合物或药物制剂的功效:燥湿祛痰,益肾活血。主治肥胖型多囊卵巢综合征,月经量少或后期,甚至闭经,纳呆、腹胀、白带量多、肢困神乏,呕恶吞酸等症。
本发明的有益效果:
本发明的药物组合物所选药材配伍相宜,组方精炼,在功能上相辅相成,以利湿除痰为目的,集祛痰、温肾、行气、健脾、活血、通利为一体,疗效显著;在药性上相制相佐,毒副反应少。
经临床效果验证,本发明的药物组合物能够改善肥胖型多囊卵巢综合征临床症状,有效降低INS、LH及T水平,减轻患者体重,促进卵泡的发育成熟、促进子宫内膜生长,提高排卵率及妊娠率。同时补肾燥湿化痰中药方以补肾化痰、调经助孕为大法,使机体达到阴阳平衡,脏腑功能协调,能明显改善患者的临床症状及中医证候,降低远期并发症风险,提高患者的生活质量,整体疗效优于西药二甲双胍与克罗米芬联合应用,值得临床推广应用。
具体实施方式
下面通过具体实例对本发明进行进一步的阐述,应该说明的是,下述说明仅是为了解释本发明,并不对其内容进行限定。
实施例1:
配方:姜半夏6克,仙灵脾30克,苍术10克,茯苓20克,陈皮12克,续断30克,香附10克,丹参20克,牛膝10克,车前子10克,肉桂6克,炙甘草6克。
制备方法:
将姜半夏、仙灵脾、苍术、茯苓、陈皮、续断、香附、丹参、牛膝、车前子、肉桂和炙甘草混合,加水煎煮两次,滤过(第一次加7-10倍量水,煎煮30分钟;第二次加5-8倍量水,煎煮20分钟),合并滤液,即得。
煎煮后的滤液口服服用,每日早晚两次,三个月经周期为一个疗程。
实施例2:
配方:姜半夏4克,仙灵脾35克,苍术8克,茯苓24克,陈皮10克,续断35克,香附8克,丹参24克,牛膝8克,车前子12克,肉桂4克,炙甘草8克。
药物组合物的制备方法同实施例1,然后以常规方法制备成胶囊剂。
实施例3:
配方:姜半夏8克,仙灵脾25克,苍术12克,茯苓16克,陈皮14克,续断25克,香附12克,丹参16克,牛膝12克,车前子8克,肉桂8克,炙甘草4克。
药物组合物的制备方法同实施例1,然后以常规方法制备成丸剂。
对比例1:
本发明人在研发过程中对具有相近药性的多味原料药进行了配伍关系的考察和药效的研究,结果发现,即使某几味原料药之间的药性相似,但与其他不同的原料药配伍使用后,其药效效果差别显著。例如:将实施例1的药物组方中陈皮、香附、续断、苍术、茯苓、牛膝和车前子替换为青皮、枳壳、杜仲、天南星、泽泻、红花和木通;用量和制备方法同实施例1。
以常规方法建立肥胖型多囊卵巢综合征动物模型,考察本发明实施例1和对比例1的中药组合物对多囊卵巢综合征的治疗效果,动物试验表明,本发明实施例1的中药组合物对于多囊卵巢综合征的治疗效果要显著优于对比例1。说明本发明的组合物符合中药的配伍关系,各组分之间具有协同促进作用,并非是具有相似药性的原料药的简单替换或组合。
对比例2:
中药组合物中各原料药的药量是标识药力的,即使方剂的药物组成相同,但若药物的用量各不相同,其药力则有大小之分,配伍关系则有君臣佐使之变,从而其功能主治则各有所异。本发明人在研发过程中对中药组合物中的各个原料含量进行了考察和药效的研究,结果发现,不合适的原料配比关系,尤其是君药和臣药所占份量的不同,其药效效果差别显著。例如:将实施例1中姜半夏的用量调整为2克,仙灵脾的用量调整为20克,陈皮的用量调整为8克,苍术的用量调整为14克,茯苓的用量调整为30克,其他原料的用量同实施例1,并按实施例1的方法制备。
以常规方法建立肥胖型多囊卵巢综合征动物模型,考察本发明实施例1和对比例2的中药组合物对多囊卵巢综合征的治疗效果,动物试验表明,本发明实施例1的中药组合物对于多囊卵巢综合征的治疗效果要显著优于对比例2。说明本发明的组合物中各原料药的用量并非是常规的调整所能得到的,本发明的中药组方中,各原料药材的用量配比是根据其药材特性、君臣佐使配伍等各种考虑因素决定的,对于中药组合物的整体药效起到非常重要的作用。
临床资料:
1.病例选择
2015年12月2016年4月就诊于山东中医药大学附属医院妇科和生殖中心门诊的肥胖型多囊卵巢综合征不孕患者108例。
2.诊断标准
(1)多囊卵巢综合征的西医诊断标准
①慢性无排卵,月经稀发或闭经或不规则子宫出血;
②高雄激素的临床表现和(或)高雄激素血症,临床表现有痤疮、多毛。高雄激素血症者血清总睾酮、游离睾酮指数或游离睾酮高于检测单位实验室正常参考值;
③超声表现为可见一侧或双侧卵巢直径2-8mm的卵泡≥12个,和/(或)卵巢体积≥10cm3。
上述项中①为必须条件加上②③中任何一项为疑似,排除其他可能引起高雄激素的疾病和引起排卵异常的疾病,如先天性肾上腺皮质增生、库欣综合征、分泌雄激素的肿瘤等,即可诊断为多囊卵巢综合征。
(2)肥胖诊断标准
BMI≥25kg/m2为肥胖。
(3)痰湿型多囊卵巢综合征中医诊断标准
主症:月经周期延后,经量少,经色淡红,质粘腻如痰;或逐渐闭经;或婚久不孕。
兼症:①胸腹痞满;②易头晕胸闷、倦怠乏力;③形体肥胖;④舌淡胖或有齿印,苔腻;⑤脉滑或沉滑。
以上主症必备,且具备兼症各项中的3项,即可诊断。
(4)不孕诊断标准:有正常性生活、未采取任何避孕措施1年仍未受孕者。
试验病例纳入标准:符合多囊卵巢综合征西医诊断标准;中医辨证属痰湿型;符合肥胖诊断标准;符合不孕诊断标准
排除标准:不符合纳入标准者;近3个月用过可能影响疗效的激素类药物;具有其他内分泌疾病或者合并有心、肝、肾等严重原发性疾病,精神病患者;合并生殖道畸形、先天性性腺发育不全、输卵管不通等器质性疾病者;不能按规定治疗或资料不全影响疗效及安全性判断者;
3.治疗方案:
将2015年12月~2016年4月就诊于山东中医药大学附属医院妇科和生殖中心门诊的符合纳入标准和排除标准的肥胖型多囊卵巢综合征患者72例。按照随机原则平均分成中药组36例和对照组36例。
其中,中药组服用实施例1制备的药物组合物,分早晚两次服用,三个月经周期为一个疗程。对照组给予二甲双胍口服,每次500mg,每日2次。同时于月经第5天开始口服克罗米芬,每次100mg,每日1次,连用5天。三个月经周期为一个疗程。
(2)疗效评定标准:
①痊愈:连续三个月经周期、经量、经期恢复正常,其他症状消失,恢复排卵或妊娠,中医症候积分疗效指数≥90%。
②显效:月经周期恢复±天,经量比治疗前增加,其他症状消失或减轻,恢复排卵或妊娠,66.67%≥中医症候积分疗效指数<90%。
③有效:治疗后月经周期、经量、经期较治疗前改善,其他症状较治疗前减轻,未恢复排卵未妊娠,33.33%≥中医症候积分疗效指数<66.67%。
④无效:治疗后月经周期、经量、经期无改善,未恢复排卵未妊娠,中医症候积分疗效指数<33.33%。
4.结果
中药组36例患者痊愈率30.56%,显效率44.44%,有效率19.44%,无效率5.56%,中药组总有效率94.44%;对照组36例患者痊愈率25%,显效率41.67%,有效率16.66%,无效率16.67%,对照组总有效率83.33%。中药组痊愈率、总有效率显著优于对照组。中药组排卵率为74.99%,妊娠率为47.22%,对照组排卵率为66.67%,妊娠率为33.33%。统计分析进行组间比较发现,治疗后2组排卵率、妊娠率有显著性差异,中药组显著优于对照组。说明本发明的药物组合物在促进患者恢复排卵的同时,从整体上调节患者内分泌代谢,改善子宫内膜容受性,使患者获得了更佳的疗效。
两组治疗后空腹胰岛素(FINS)、胰岛素抵抗指数均较治疗前显著改善,中药组在临床证候评分、降低体重指数、血清性激素下降方面(尤其降低雄激素方面)疗效优于对照组,差异具有显著性。并且治疗中未出现不良反应,说明本发明的药物组合安全有效。
5.结论:
补肾燥湿化痰中药方能够改善肥胖型多囊卵巢综合征临床症状,有效降低INS、LH及T水平,减轻患者体重,促进卵泡的发育成熟、促进子宫内膜生长,提高排卵率及妊娠率。同时补肾燥湿化痰中药方以补肾化痰、调经助孕为大法,使机体达到阴阳平衡,脏腑功能协调,能明显改善患者的临床症状及中医证候,降低远期并发症风险,提高患者的生活质量,整体疗效优于西药二甲双胍与克罗米芬联合应用,值得临床推广应用。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术的技术人员在本发明批露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (8)
1.一种治疗肥胖型多囊卵巢综合征的药物组合物,其特征在于,其原料组成为:
姜半夏4-8份,仙灵脾25-35份,苍术8-12份,茯苓16-24份,陈皮10-14份,续断25-35份,香附8-12份,丹参16-24份,牛膝8-12份,车前子8-12份,肉桂4-8份,炙甘草4-8份。
2.如权利要求1所述的药物组合物,其特征在于,其原料组成为:
姜半夏6份,仙灵脾30份,苍术10份,茯苓20份,陈皮12份,续断30份,香附10份,丹参20份,牛膝10份,车前子10份,肉桂6份,炙甘草6份。
3.权利要求1或2所述的药物组合物的制备方法,其特征在于,步骤如下:
将姜半夏、仙灵脾、苍术、茯苓、陈皮、续断、香附、丹参、牛膝、车前子、肉桂和炙甘草混合,加水煎煮,滤过,合并滤液,即得。
4.如权利要求3所述的制备方法,其特征在于,水煎煮的具体操作为:第一次加7-10倍量水,煎煮30分钟;第二次加5-8倍量水,煎煮20分钟。
5.权利要求1或2所述的药物组合物在制备治疗肥胖型多囊卵巢综合征的药物制剂中的用途。
6.一种治疗肥胖型多囊卵巢综合征的药物制剂,由权利要求1或2所述的药物组合物和药学上可接受的辅料制备而成。
7.如权利要求6所述的药物制剂,其特征在于,所述药学上可接受的辅料为崩解剂、润滑剂或黏合剂。
8.如权利要求6所述的药物制剂,其特征在于,所述药物制剂的剂型为丸剂、胶囊剂、片剂、散剂、颗粒剂或口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610955074.XA CN106334060B (zh) | 2016-11-03 | 2016-11-03 | 一种治疗肥胖型多囊卵巢综合征的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610955074.XA CN106334060B (zh) | 2016-11-03 | 2016-11-03 | 一种治疗肥胖型多囊卵巢综合征的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106334060A true CN106334060A (zh) | 2017-01-18 |
CN106334060B CN106334060B (zh) | 2021-06-08 |
Family
ID=57841571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610955074.XA Expired - Fee Related CN106334060B (zh) | 2016-11-03 | 2016-11-03 | 一种治疗肥胖型多囊卵巢综合征的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106334060B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107320599A (zh) * | 2017-07-10 | 2017-11-07 | 孙海燕 | 一种用于治疗多囊卵巢综合症的中药制剂 |
CN108542907A (zh) * | 2018-07-05 | 2018-09-18 | 厦门大学 | 一种茯苓酸或茯苓酸衍生物用于制备治疗多囊卵巢综合症药物的应用及药物制剂 |
CN108853427A (zh) * | 2018-08-02 | 2018-11-23 | 中山大学附属第医院 | 一种治疗超重/肥胖型多囊卵巢综合征的中药方剂 |
CN115068578A (zh) * | 2022-06-22 | 2022-09-20 | 中国中医科学院广安门医院 | 一种治疗胰岛素抵抗型多囊卵巢综合征的中药组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104162094A (zh) * | 2014-05-05 | 2014-11-26 | 中国人民解放军第二军医大学 | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 |
CN104162057A (zh) * | 2014-08-26 | 2014-11-26 | 上海市闸北区中医医院 | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其应用 |
CN104491295A (zh) * | 2015-01-17 | 2015-04-08 | 河南中医学院 | 一种治疗多囊卵巢综合征的中药组合物 |
CN105816617A (zh) * | 2016-04-29 | 2016-08-03 | 山东省立医院 | 一种治疗肥胖型多囊卵巢综合征的中药组合物 |
CN105853659A (zh) * | 2016-06-15 | 2016-08-17 | 山东中医药大学附属医院 | 一种治疗多囊卵巢综合征的中药组合物 |
-
2016
- 2016-11-03 CN CN201610955074.XA patent/CN106334060B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104162094A (zh) * | 2014-05-05 | 2014-11-26 | 中国人民解放军第二军医大学 | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 |
CN104162057A (zh) * | 2014-08-26 | 2014-11-26 | 上海市闸北区中医医院 | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其应用 |
CN104491295A (zh) * | 2015-01-17 | 2015-04-08 | 河南中医学院 | 一种治疗多囊卵巢综合征的中药组合物 |
CN105816617A (zh) * | 2016-04-29 | 2016-08-03 | 山东省立医院 | 一种治疗肥胖型多囊卵巢综合征的中药组合物 |
CN105853659A (zh) * | 2016-06-15 | 2016-08-17 | 山东中医药大学附属医院 | 一种治疗多囊卵巢综合征的中药组合物 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107320599A (zh) * | 2017-07-10 | 2017-11-07 | 孙海燕 | 一种用于治疗多囊卵巢综合症的中药制剂 |
CN108542907A (zh) * | 2018-07-05 | 2018-09-18 | 厦门大学 | 一种茯苓酸或茯苓酸衍生物用于制备治疗多囊卵巢综合症药物的应用及药物制剂 |
CN108853427A (zh) * | 2018-08-02 | 2018-11-23 | 中山大学附属第医院 | 一种治疗超重/肥胖型多囊卵巢综合征的中药方剂 |
CN115068578A (zh) * | 2022-06-22 | 2022-09-20 | 中国中医科学院广安门医院 | 一种治疗胰岛素抵抗型多囊卵巢综合征的中药组合物及其应用 |
CN115068578B (zh) * | 2022-06-22 | 2023-06-23 | 中国中医科学院广安门医院 | 一种治疗胰岛素抵抗型多囊卵巢综合征的中药组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106334060B (zh) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060141071A1 (en) | Compositions and methods for treating gynecological disorders | |
CN104162094B (zh) | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 | |
CN106362104A (zh) | 一种治疗青春期多囊卵巢综合征的药物组合物 | |
CN106334060A (zh) | 一种治疗肥胖型多囊卵巢综合征的药物组合物 | |
CN101375968A (zh) | 一种中药组合物及其制备方法和用途 | |
CN101797301A (zh) | 一种预防和治疗中老年便秘的药物 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN102120020A (zh) | 一种治疗乳腺增生病和子宫肌瘤的药物组合物及其制备方法 | |
CN103948782B (zh) | 一种治疗肝郁气滞型乳腺增生的药物组合物及其制备方法和用途 | |
CN102861148B (zh) | 一种治疗原发性痛经的中药制剂及制备方法与应用 | |
CN101332282B (zh) | 一种治疗肾虚阴冷所致妇科疾病的中药组合物及制备方法 | |
CN100391494C (zh) | 一种治疗痛证的中药复方制剂及其制备方法 | |
CN1879838A (zh) | 一种治疗先兆性流产的中药 | |
CN113599475B (zh) | 一种治疗多囊卵巢综合征的温中补肾组合物及其制备方法与应用 | |
CN102188522B (zh) | 一种治疗便秘的中药组合物 | |
CN102125671B (zh) | 一种治疗肾虚阴冷所致妇科疾病的中药组合物及制备方法 | |
CN101664533A (zh) | 一种治疗急慢性乳腺增生的中药及制备方法 | |
CN109200162B (zh) | 一种治疗多囊卵巢综合征的中药制剂及制备方法 | |
CN110237161A (zh) | 用于治疗绝经综合征的药物及其制备方法和应用 | |
CN100475253C (zh) | 一种治疗不孕症、月经不调、痛经、内分泌失调及骨质疏松的药物 | |
CN102697955A (zh) | 一种治疗妇科疾病的药物 | |
CN109549984B (zh) | 一种用于治疗不孕不育的中药组合物 | |
CN106540168B (zh) | 一种治疗肾虚型月经不调、闭经及不孕症的中药组合物及制备方法、应用 | |
CN106943506B (zh) | 一种治疗更年期综合征的药物组合物及其制备方法 | |
CN105232609A (zh) | 一种治疗功能性消化不良的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210608 Termination date: 20211103 |